Denali's Investigational Treatment Approach to Hunter syndrome

Brain delivery is a critical unmet need in Hunter syndrome therapy1

Treatments that cross the blood-brain barrier and aim to treat the neurocognitive components of Hunter syndrome, such as developmental delay, disruptive behavior and impaired cognition, remain a critical unmet medical need.

Visit our corporate website to read recent press releases on our DNL310 program

Learn More About Clinical Trials

Whether you’re interested in active participation or just want to know about research in progress, see our latest clinical trial information here

References: 1. R. J. Desnick, E. H. Schuchman, Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges. Annu. Rev. Genomics Hum. Genet. 13, 307–335 (2012). 2. Kariolis et al., Sci. Transl. Med. 12, eaay1359 (2020) 27 May 2020 3. Ullman et al., Sci. Transl. Med. 12, eaay1163 (2020) 27 May 2020

Representation of a 2-sided flyer offering a Spanish translation of the Engage Hunter website

Ver información en español y su contenido están destinados a audiencias en los Estados Unidos. and its content are intended for United States audiences.